Silibinin exerts antidepressant effects by improving neurogenesis through BDNF/TrkB pathway

Publication date: 1 August 2018
Source:Behavioural Brain Research, Volume 348
Author(s): Yan-Jiao Li, Yu-Jiao Li, Liu-Di Yang, Kun Zhang, Kai-Yin Zheng, Xin-Miao Wei, Qi Yang, Wen-Min Niu, Ming-Gao Zhao, Yu-Mei Wu
Classic antidepressants benefit depression patients partially by improving neurogenesis and/or brain-derived neurotrophic factor (BDNF)/TrkB pathway which were impaired in depression. In this study, we demonstrated that Silibinin (SLB), a polyphenolic flavanoid from Silybum marianum, ameliorated reserpinized mouse depressant-like behaviors. The antidepressants of SLB administration was associated with increased neural stem cells (NSCs) proliferation and further confirmed in BDNF/TrkB signaling transduction. SLB treatment reversed the decreased expression levels of BDNF and its receptor TrkB, and the reduced activation of downstream target proteins including phosphorylated extracellular-regulated protein kinase (p-ERK) and phosphorylated cAMP-response element binding protein (p-CREB) in depressived hippocampus. Furthermore, intracerebroventricular injection of GNF5837, a TrkB antagonist, abrogated antidepressant-like effects of SLB in mice along with the improved NSC proliferation, as well as enhanced levels of p-ERK and p-CREB in mice hippocampus. Taken together, these results suggest that SLB may exert antidepressant effects through BDNF/TrkB signaling pathway to improve NSC proliferation in acute depression.



https://ift.tt/2HZX6H2